Emapalumab

Descripción

Emapalumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IFNG, Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. 1, 5 The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy. 5 As well, emapalumab was given the status of PRIME by the EMA.